Avid Bioservices Inc (CDMO)

[biopharm]

CP, when you say they can buy now ...is that in reference to poison pill off the table now as well?

More curious is why these ex Eli Lilly folks below, that work for Omeros...are stressing there are indeed TWO brakes holding up the immune system and PS Targeting is one of them

Laura Benjamin and Oncologie multiple ex Eli Lilly as well

Arnold Hanish / Omeros ties Eli Lilly

David Monteith / Omeros ties Eli Lilly

Tom Bumol / Omeros ties Eli Lilly

Catherine A Melfi / Omeros ties Eli Lilly


The new cancer-immunotherapy approach is based on a series of discoveries by Omeros related to GPR174, which include:

The identification of phosphatidylserine (PS) as a potent natural ligand for GPR174

....
....
these receptors are activated by molecules (i.e., PS and adenosine, respectively) that are highly enriched in the tumor microenvironment. Strikingly, in experiments with total human peripheral blood mononuclear cells (PBMCs) where PS and adenosine are naturally abundant, GPR174 inhibitors synergized with A2A/A2B inhibitors to increase T-cell responses dramatically.

....
....
Our GPR174-related discoveries open a wholly new approach to targeting the tumor microenvironment for cancer immunotherapy, said Marc Gavin, Ph.D., Omeros director of immunology who previously pioneered research on cAMP signaling in regulatory T cells and initiated and led Amgens groundbreaking IL-2 mutein program.
...
....
Furthermore, the discovery that PS itself stimulates an immunosuppressive GPCR namely GPR174 on all lymphocytes represents a significant advancement in our understanding of how PS regulates tumor immunity.

...
....
Relevance of Findings

Omeros findings are also particularly relevant for patients resistant to checkpoint inhibitors, such as anti-PD-1 (e.g., Keytruda and Opdivo) and anti-CTLA-4 (Yervoy), and to emerging cellular therapies such as CAR-T cells and adoptive T-cell therapy. Checkpoint inhibitors are only effective in a minority of patients, and high levels of adenosine-generating molecules have been observed in non-responding patients. Furthermore, overcoming natural immunosuppression in solid tumors represents a major hurdle for cellular therapies. Because PS and adenosine are both products of cell stress and death in solid tumors, it is expected that patients resistant to checkpoint inhibitors or cellular therapies would benefit greatly from the combined inhibition of the GPR174 and adenosine pathways.

“Our team’s discovery of the GPR174-controlled cancer-immunity pathways and their interrelationships with the adenosine pathway have been methodically elucidated and defined,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer. “Simply put, Omeros has discovered that there are two feet on the cAMP brake pedal restraining immunity against the tumor and, to enable effective tumor-killing activity, both GPR174 and the adenosine pathway must be inhibited. We are optimizing our small-molecule GPR174 inhibitors with the objective of moving orally available therapeutics into the clinic as rapidly as possible. We look forward to providing physicians and patients with a new and broadly applicable option in cancer immunotherapy.”

Omeros is preparing a manuscript for publication detailing its GPR174-related discoveries and data and plans to present these same discoveries and data beginning this year at upcoming oncology international congresses.

Omeros is establishing an expansive and exclusive intellectual property position directed to GPR174 inhibitors as well as to inhibition of the GPR174 receptor, both alone and in combination with other cancer therapies, for the treatment of any tumor or malignancy.
_________


Omeros Discovers New Cancer-Immunity Pathways Controlled by GPR174

Published: Sep 10, 2019

https://www.biospace.com/article/releases/omeros-discovers-new-cancer-immunity-pathways-controlled-by-gpr174/

_________

Some highlights below from above article and READ the entire article, this is another group with â??unpublishedâ? research data on PtdSer / PS / Phosphatidylserine and how it is REQUIRED for treating cancer

"PS REGULATES TUMOR IMMUNITY"

..and H.C. Wainwright covers both Omeros and Avid CDMO which is why I believe they updated price target to Avid at $11 but why is Oncologie Inc and Avid not pointing this out to investors?????

Fiduciary Duties are at stake and clear to see they are manipulating the pps to keep it low
___




Omeros Discovers New Cancer-Immunity Pathways Controlled by GPR174

Published: Sep 10, 2019

https://www.biospace.com/article/releases/omeros-discovers-new-cancer-immunity-pathways-controlled-by-gpr174/
____

...some highlights of above pasted below:



The new cancer-immunotherapy approach is based on a series of discoveries by Omeros related to GPR174, which include:

The identification of phosphatidylserine (PS) as a potent natural ligand for GPR174

...
...
these receptors are activated by molecules (i.e., PS and adenosine, respectively) that are highly enriched in the tumor microenvironment. Strikingly, in experiments with total human peripheral blood mononuclear cells (PBMCs) where PS and adenosine are naturally abundant, GPR174 inhibitors synergized with A2A/A2B inhibitors to increase T-cell responses dramatically.

...
...
Our GPR174-related discoveries open a wholly new approach to targeting the tumor microenvironment for cancer immunotherapy, said Marc Gavin, Ph.D., Omeros director of immunology who previously pioneered research on cAMP signaling in regulatory T cells and initiated and led Amgens groundbreaking IL-2 mutein program.
..
...
Furthermore, the discovery that PS itself stimulates an immunosuppressive GPCR namely GPR174 on all lymphocytes represents a significant advancement in our understanding of how PS regulates tumor immunity.

..
...
Relevance of Findings

Omeros findings are also particularly relevant for patients resistant to checkpoint inhibitors, such as anti-PD-1 (e.g., Keytruda and Opdivo) and anti-CTLA-4 (Yervoy), and to emerging cellular therapies such as CAR-T cells and adoptive T-cell therapy. Checkpoint inhibitors are only effective in a minority of patients, and high levels of adenosine-generating molecules have been observed in non-responding patients. Furthermore, overcoming natural immunosuppression in solid tumors represents a major hurdle for cellular therapies. Because PS and adenosine are both products of cell stress and death in solid tumors, it is expected that patients resistant to checkpoint inhibitors or cellular therapies would benefit greatly from the combined inhibition of the GPR174 and adenosine pathways.